within Pharmacolibrary.Drugs.ATC.R;

model R05CA01
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 8.333333333333334e-06,
    adminDuration  = 600,
    adminMass      = 240 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.01,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R05CA01</td></tr><td>route:</td><td>inhalation</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Tyloxapol is a nonionic liquid polymer derived from a partial polyglycol ester of an alkyl aryl polyether alcohol, used mainly as a surfactant for mucolytic purposes in respiratory therapy. It has been used to facilitate mucus clearance by reducing viscosity, primarily in inhaled formulations in conditions such as bronchitis or cystic fibrosis. Tyloxapol is not widely used today; it is not approved as a primary therapeutic agent in most countries.</p><h4>Pharmacokinetics</h4><p>No published human or animal pharmacokinetic (PK) models or parameters for tyloxapol could be identified in the literature. The following parameters are estimated/proposed based on its administration route and physicochemical properties as a mucolytic agent used via inhalation.</p><h4>References</h4><ol><li><p>He, J, et al., &amp; Lu, Y (2019). Evaluation of inhaled recombinant human insulin dry powders: pharmacokinetics, pharmacodynamics and 14-day inhalation. <i>The Journal of pharmacy and pharmacology</i> 71(2) 176–184. DOI:<a href=\"https://doi.org/10.1111/jphp.13026\">10.1111/jphp.13026</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30324757/\">https://pubmed.ncbi.nlm.nih.gov/30324757</a></p></li><li><p>Marcinkowski, AL, et al., &amp; Corcoran, TE (2008). Postdeposition dispersion of aerosol medications using surfactant carriers. <i>Journal of aerosol medicine and pulmonary drug delivery</i> 21(4) 361–370. DOI:<a href=\"https://doi.org/10.1089/jamp.2008.0699\">10.1089/jamp.2008.0699</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18800882/\">https://pubmed.ncbi.nlm.nih.gov/18800882</a></p></li><li><p>Suga, K, et al., &amp; Alderson, PO (1998). Effect of inhaled surfactant on pulmonary deposition and clearance of technetium-99m-DTPA radioaerosol. <i>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</i> 39(3) 543–547. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9529308/\">https://pubmed.ncbi.nlm.nih.gov/9529308</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R05CA01;
